THC Screen; THC and metabolites Screen; Cannabis
Back to Test Catalogue
Cannabinoids Screen, Random Urine
Test ID: THC UHSC
Test
Aliases/Synonyms
Method
Enzyme Immunoassay
Method Description
The homogeneous enzyme immunoassay uses monoclonal antibodies that detect the major metabolite of Δ9-THC in urine. The assay is based on the competition between an enzyme labeled drug and the drug from the urine for a fixed number of specific antibody binding sites. In the absence of drug from the sample, the specific antibody binds to the drug labeled with glucose-6-phosphate dehydrogenase (G6PDH) and the enzyme activity is inhibited. This phenomenon creates a direct relationship between the drug concentration in the urine and the enzyme activity. The G6PDH enzyme activity is determined spectrophotometrically by measuring its ability to convert nicotinamide adenine dinucleotide (NAD) to NADH.
(Source: Architect Cannabinoids kit insert August 2016)
Platform
Abbott Architect
Report Includes
Creatinine; Cannabinoid Screen
Specimens
Urine (Random)
Clinical Utility
The principal active agent in marijuana and/or hashish that produces hallucinogenic and other biological effects is generally accepted to be Δ9-tetrahydrocannabinol (Δ9-THC). Δ9-THC is rapidly absorbed and almost completely metabolized by inhalation or through the gastrointestinal tract. Peak plasma levels of Δ9-THC occur within 10 minutes of inhalation and approximately 1 hour after ingestion. About 70% of a THC dose is excreted within 72 hours with 30% in urine and 40% in feces. In chronic users, THC may accumulate in fatty tissue faster than it can be excreted. This leads to longer detection times in urine for chronic users than for occasional users.
(Source: Architect Cannabinoids kit insert August 2016)
Test Location
Hospital for Sick Children, 555 University Avenue, Toronto ON M5G 1X8
Test Version
27-Nov-2019
Specimen
Specimens
Urine (Random)
Sample Volume
10 mL
Collection & Handling
Handling Information
Transport cold.
Test Version
27-Nov-2019
Performance / Interpretation
Method
Enzyme Immunoassay
Method Description
The homogeneous enzyme immunoassay uses monoclonal antibodies that detect the major metabolite of Δ9-THC in urine. The assay is based on the competition between an enzyme labeled drug and the drug from the urine for a fixed number of specific antibody binding sites. In the absence of drug from the sample, the specific antibody binds to the drug labeled with glucose-6-phosphate dehydrogenase (G6PDH) and the enzyme activity is inhibited. This phenomenon creates a direct relationship between the drug concentration in the urine and the enzyme activity. The G6PDH enzyme activity is determined spectrophotometrically by measuring its ability to convert nicotinamide adenine dinucleotide (NAD) to NADH.
(Source: Architect Cannabinoids kit insert August 2016)
Platform
Abbott Architect
Turnaround Time
2 days
Results
| Name | Units | Reference Range | Conversion Factor | |
|---|---|---|---|---|
| Creatinine | mmol/L |
|
||
| Cannabinoid Metabolites Screen | µg/L |
|
||
|
This assay can detect:
11-Hydroxy-Δ9-THC I-11-nor-Δ8-THC-COOH I-11-nor-Δ9-THC-COOH 8-β-Hydroxy-Δ9-THC 8-β-11-Hydroxy-Δ9-THC Δ9-THC Cannabinol |
||||
Test Location
Hospital for Sick Children, 555 University Avenue, Toronto ON M5G 1X8
Test Version
27-Nov-2019
Interface / Setup
HL7 Interface Codes
| Order Code | Result Codes | Units |
|---|---|---|
| THC UHSC | 38474Creatinine,urine | mmol/L |
| 38478Cannabinoid Metab Screen,urine | ug/L |
Test Version
27-Nov-2019